SAGE insider buying & filings

SAGESage Therapeutics, Inc.

—

13 insider filings on record.
None of them an open-market buy in the last year.

Last Form 4 Jul 31 · scanned 6m ago

No price data yet — the yfinance scanner hasn't produced bars for SAGE.

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

Short % float

Pro

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Jul 31RETURNShiferman Gregory L.See Remarksdirect23,735 sh—

Jul 31OTHERShiferman Gregory L.See Remarksdirect7,215 sh—

Jul 31RETURNQuirk Michael C.See Remarksdirect7,962 sh—

Jul 31RETURNQuirk Michael C.See Remarksdirect24,999 sh—

Jul 31RETURNGreene Barry EPresident and CEOdirect53,229 sh—

Context

Coverage

The file stays open

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice